GlaxoSmithKline toes the line in Breo launch

Does the Justice Department's off-label marketing enforcement actually deter bad behavior? That's been up for debate as one drugmaker after another agreed to pay hundreds of millions of dollars to settle federal investigations--some of them repeat offenders. Some drugmakers appear to be changing their behavior, though, Bloomberg reports--not out of the goodness of their hearts, but out of self-interest. Story

Suggested Articles

An inhaled drug developed by Aridis eradicated the novel coronavirus from infected hamsters at a much lower dose than other antibody treatments.

The financing positions SparingVision to fund clinical trials of an AAV gene therapy that could stop vision deterioration in 2 million patients.

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.